News & Updates

Clinical role of oral bempedoic acid in LDL-C management

LDL-cholesterol (LDL-C) reduction is the key to preventing and treating atherosclerotic cardiovascular disease (ASCVD). Recent guidelines advocate aggressive LDL-C lowering in individuals at high or very high cardiovascular (CV) risk. At the Advances in Medicine 2024 conference, Dr Chu-Pak Lau, Specialist in Cardiology, discussed the clinical role of non-statin lipid-lowering therapies (LLTs), including oral bempedoic acid as a single agent or in fixed-dose combination (FDC) with ezetimibe, in patients who have failed to achieve guideline-recommended LDL-C targets or have statin intolerance.

Robust evidence for fenofibrate in patients with metabolic syndrome on statins

Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF

The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.

NOACs in nonvalvular atrial fibrillation with multimorbidity: Where does apixaban stand?

Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice, affecting millions of people globally. Stroke is one of its devastating complications, with the risk steeply increasing with advancing age. Additionally, AF is associated with more than a tripling of the risk of systemic embolic (SE) events. [J Am Heart Assoc 2020;9:e016724]